Polykinase Inhibitor Nanoparticles for Predictable Checkpoint Inhibitor Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, have unpredictable efficacy in treating cancer, with most patients not deriving benefit due to complex negative feedback loops that prevent effective immune response.
Innovation Solution
Development of nanoparticles containing hydrophobic kinase inhibitors, such as curcuminoids, optionally co-loaded with chemotherapy agents like doxorubicin, which are administered in combination with anti-PD-1/PD-L1/PD-L2 antibodies to enhance tumor-specific T-cell immunity and overcome immunosuppressive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) are used to treat cancer, then tumor-specific T-cell immunity is enhanced, but efficacy remains unpredictable and majority of patients do not derive benefit
Solution Approach 1:
The patent applies preliminary action by administering polykinase inhibitor-loaded nanoparticles before the checkpoint inhibitor antibody. The nanoparticles are given 1-24 hours prior to the antibody, allowing the polykinase inhibitor to pre-treat the tumor microenvironment and prime the immune system, thereby improving the subsequent efficacy of the checkpoint inhibitor in a predictable manner
Solution Approach 2:
The patent uses polykinase inhibitor-loaded nanoparticles as an intermediary substance between the patient and the checkpoint inhibitor antibody. These nanoparticles mediate the interaction by delivering polykinase inhibitors that modulate the tumor microenvironment, enhancing the antibody's ability to activate T-cell immunity and improving response predictability
2Reliability
If higher doses of anti-PD-1/PD-L1 antibodies are used to improve efficacy, then anti-tumor response increases, but treatment cost and toxicity increase
Solution Approach 1:
By administering polykinase inhibitor-loaded nanoparticles 1-24 hours before the checkpoint inhibitor antibody, the system prepares the tumor microenvironment in advance. This preliminary treatment enhances the antibody's effectiveness, allowing lower antibody doses to achieve the same anti-tumor response that would otherwise require higher doses
Solution Approach 2:
The patent employs composite material principles by combining polykinase inhibitors and checkpoint inhibitor antibodies into a coordinated treatment system. The nanoparticles carrying polykinase inhibitors work synergistically with the antibody, creating a composite therapeutic effect that enhances tumor-specific T-cell immunity at lower antibody doses
Data Source
AI summary
The invention disclosed herein relates to nanoparticles containing one or more polykinase inhibitors and methods of using the same in combination with checkpoint inhibitors to treat cancer.